Page last updated: 2024-12-05
2-hydroxyquinoxaline
Description
2-Hydroxyquinoxaline is a heterocyclic compound with a broad range of biological activities, including antibacterial, antifungal, and anticancer properties. Its synthesis often involves the condensation of o-phenylenediamine with a suitable α-hydroxycarbonyl compound. The compound has shown promise in various studies, exhibiting significant inhibitory effects against certain bacterial strains and fungal species. Its unique structural features, particularly the presence of the hydroxyl group, contribute to its biological activity. The compound is often studied to explore its potential as a drug candidate for various infectious diseases and conditions.'
quinoxalin-2-ol : A hydroxyquinoxaline that consists of quinoxaline having a single hydroxy substituent located at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 14526 |
CHEBI ID | 38890 |
SCHEMBL ID | 37862 |
MeSH ID | M0258908 |
Synonyms (65)
Synonym |
ai3-22771 |
nsc 13154 |
einecs 214-815-6 |
BB 0218319 |
quinoxalin-2-ol |
AB-323/25048501 |
2-quinoxalinone |
nsc-13154 |
2-hydroxyquinoxaline |
1196-57-2 |
2(1h)-quinoxalinone |
nsc13154 |
quinoxalin-2-one |
3-quinoxalinone |
2-quinoxalinol |
wln: t66 bn enj cq |
2-quinoxalone |
2-hydroxy quinoxaline |
inchi=1/c8h6n2o/c11-8-5-9-6-3-1-2-4-7(6)10-8/h1-5h,(h,10,11 |
2-quinoxalinol, 99% (hplc) |
HMS1623H17 |
1h-quinoxalin-2-one |
H0591 |
AKOS000120904 |
AKOS003236140 |
A804334 |
STL139322 |
quinoxalin-2(1h)-one |
1,2-dihydroquinoxalin-2-one |
144499-26-3 |
quinoxalin-2-(1h)-one |
FT-0688667 |
2-quinoxinol |
CHEBI:38890 |
FT-0612639 |
AM100249 |
SCHEMBL37862 |
quinoxalinone |
2-keto-1,2-dihydroquinoxaline |
quinoxaline-2-ol |
2-hydroxy-benzopyrazine |
DTXSID6061604 |
SY013680 |
mfcd00006722 |
TS-01898 |
2-quinoxalinol(9ci) |
W-108501 |
AC-23582 |
F1775-0040 |
Z56824051 |
CS-W018235 |
F16123 |
Q27118020 |
CCG-321752 |
BCP30468 |
2-hydroxyquinoxaline pound>>quinoxalin-2-ol pound>>quinoxalin-2(1h)-one pound>>1,2-dihydroquinoxalin-2-one |
EN300-16930 |
doi:10.14272/ffryuavnpbueic-uhfffaoysa-n.1 |
10.14272/FFRYUAVNPBUEIC-UHFFFAOYSA-N.1 |
quinalphos free hydroxy |
P50007 |
doi:10.14272/ffryuavnpbueic-uhfffaoysa-n.2 |
10.14272/FFRYUAVNPBUEIC-UHFFFAOYSA-N.2 |
10.14272/FFRYUAVNPBUEIC-UHFFFAOYSA-N.3 |
doi:10.14272/ffryuavnpbueic-uhfffaoysa-n.3 |
Roles (1)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
hydroxyquinoxaline | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 32.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 32.30 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.96 (4.65) | Search Engine Demand Index | 35.70 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |